Generalized thyroid hormone resistance (GTHR) is a disorder of thyroid hormone action that we have previously shown to be tightly linked to one of the two thyroid hormone receptor genes, c-erbA,8, in a single kindred, A. We now show that in two other kindreds, B and D, with differing phenotypes, there is also linkage between c-erbAft and GTHR. The combined maximum logarithm of the odds score for all three kindreds at a recombination fraction of 0 was 5.77. In vivo studies had shown a triiodothyronine (T3)-binding affinity abnormality in nuclear receptors of kindred A, and we therefore investigated the defect in c-erbA,8 in this kindred by sequencing a major portion of the T3-binding domain in the 3'-region of fibroblast c-erbAfl cDNA and leukocyte c-erbAf genomic DNA. A base substitution, cytosine to adenine, was found at cDNA position 1643 which altered the proline codon at position 448 to a histidine. By allelic-specific hybridization, this base substitution was found in only one allele of seven affected members, and not found in 10 unaffected members of kindred A, as expected for a dominant disease. Also, this altered base was not found in kindreds B or D, or in 92 random c-erbA,8 alleles. These results and the fact that the mutation is predicted to alter the secondary structure of the crucial T3-binding domain of the c-erbAft receptor suggest this mutation is an excellent candidate for the genetic cause of GTHR in kindred A. Different mutations in the c-erbAfl gene are likely responsible for the variant phenotypes of thyroid hormone resistance in kindreds B and D. (J. Clin. Invest. 1990.85:93-100.) linkage -candidate mutation -proline codon 448 * histidine -triiodothyronine-binding domain
Introduction
Generalized thyroid hormone resistance (GTHR)' refers to a syndrome characterized by elevated circulating levels of free thyroid hormones, resistance to thyroid hormone action, and inappropriately normal or elevated levels of thyroid-stimulat-ing hormone (1) . Refractoriness to thyroid hormones was first noted by Refetoff et al. (2) in two siblings with stippling of the epiphyses characteristic ofjuvenile hypothyroidism, short stature, and multiple somatic abnormalities. The mode of transmission in the original kindred was unclear; however, it now appears that, in most patients with GTHR, the syndrome segregates as an autosomal dominant disorder, the patients have no somatic abnormalities, and the degree of tissue refractoriness to thyroid hormone action is variable among different kindreds (3) . In one variant of thyroid hormone resistance, selective pituitary resistance (4, 5) the pituitary gland is more refractory than peripheral tissues to thyroid hormones, and hyperthyroidism results from abnormal control of thyrotropin-secreting hormone (TSH) secretion. A single case of selective peripheral but not pituitary resistance has been found (6) .
It is generally accepted that thyroid hormones regulate gene function through interactions with a nuclear receptor (7, 8) . Thus, several workers have performed studies of labeled triiodothyronine (T3) binding to nuclei from fibroblasts or lymphocytes in patients with GTHR (9) . Although certain workers using these methods have reported small abnormalities of T3-binding affinity or number, most of these reports showed no binding abnormalities (9) . Subsequently, it was shown that kinetic methods of analysis might be more sensitive than equilibrium methods in defining T3-binding abnormalities (9) . Recently, new methods of salt extraction of fibroblast nuclear receptors have suggested abnormal T3-binding affinities or capacities in certain patients with thyroid hormone resistance (10, 1 1). However, these extraction methods are relatively cumbersome and imprecise, and it has not been possible with such technology to establish unequivocally that any patients with GTHR have abnormalities of the nuclear receptor for T3.
A major advance enabling further insights into thyroid hormone action was made when two genes, c-erbAa (chromosome 17) and c-erbA,3 (chromosome 3), were identified that encode proteins with properties of a T3 receptor (12, 13). Although the native T3 receptor has not yet been fully characterized, the c-erbA# cDNA cloned human placenta (c-erbA#il) and the c-erbAf3a cDNA (al) cloned from embryonal chicken tissue have been used to synthesize proteins that bind T3 with high affinity, and with the specificity of a T3 receptor. There are multiple-receptor forms or isotypes encoded by these a and iB genes. The c-erbAa 1 mRNA has been shown in vitro to encode a protein which binds T3 with high affinity and is expressed in a wide range of tissues (14, 15). In particular, it is found in high abundance in specific regions of the rat central nervous system (16) . An alternatively spliced form, c-erbAa2, is not a T3 receptor, but can bind to thyroid hormone-respon-sive elements in genes in vitro and may have a role in modulating T3-regulated expression (17) (18) (19) (20) . The a2 message is more abundant than al in the rat brain (16) . In addition to the original c-erbAjB cDNA cloned from human placenta, another (l-isoform, c-erbA,32, has been identified which appears to be expressed only in the rat anterior pituitary gland (21) . However, no specific in vivo function has yet been determined for any of these receptor forms and their relative physiologic role in humans is not known.
We have shown in one kindred, A, that the gene for GTHR maps to the same region as c-erbA# (22) . Recent studies have
shown that there is a single human c-erbA# gene (Bradley, W. E. C., Institut du Cancer, Montreal, Canada, personal communication). The tight linkage between a gene that codes for a thyroid hormone receptor and a syndrome with abnormal thyroid hormone action strongly suggests that the syndrome of GTHR in kindred A results from a mutation in c-erbAfl, and that c-erbA# has important in vivo functions in diverse human tissues.
In the present study, we present partial cDNA and genomic sequence data from kindred A and identify a base substitution at the COOH terminus of c-erbA3 which is not a polymorphism. This variant sequence can be used to identify unequivocally future affected members of kindred A, thereby enabling rapid diagnosis. Although it has not been proved to be the cause of the syndrome in kindred A, it is an excellent candidate mutation for the genetic etiology of abnormal c-erbA# function. We have also shown linkage of c-erbA# to GTHR in two additional kindreds. These kindreds, although similar in having features of pituitary and peripheral resistance to thyroid hormones, have distinct features presumably related to differences in tissue regulation by thyroid hormones. Both kindreds lack the mutation seen in kindred A. These new linkage data underscore that there is a crucial role for c-erbA# in humans and suggest that differing mutations of c-erbA# may be responsible for differing patterns of resistance to thyroid hormone action.
Methods
Clinical studies. Clinical data on members of kindreds A, B, and D were obtained during hospitalizations at the Clinical Center of the National Institutes of Health. All patients were entered into Clinical Center protocols and gave informed consent. Serum thyroxine (T4), free thyroxine (FT4), T3, and TSH were measured at the Clinical Center and corroborated by Hazelton Biotechnologies (Vienna, VA). The clinical criteria used to assess thyroid hormone action in target tissues in kindreds A, B, and D have been previously defined (3 Genetic studies. DNA samples from kindreds B and D were prepared from leukocytes as described for the original kindred A (22) . The c-erbAft cDNA probe (Phe A12) was used to identify restriction fragment length polymorphisms (RFLPs) with BamHI and EcoRV at the c-erbA# locus as previously described (22) . Linkage analysis in kindreds B and D were performed using the program LIPED with the assumptions of complete penetrance, a gene frequency of 10-', and equal male and female recombination rates (24) .
Isolation and characterization of c-erbAf sequences from kindred A. Total RNA specimens from pituitary fibroblast cultures ofmembers of kindred A were prepared by lysis in guanidine isothiocyanate and ultracentrifugation through a cesium chloride gradient (25) . Reverse transcription of these specimens was according to a previously published method (26). The antisense primer (ASl) used for first-stand synthesis was specific for the noncoding region of c-erbAft cDNA and had a thymine substitution to produce an EcoRI site for subcloning purposes: 5'-GGAATTATAGGAAGGAATTCAGTCAGT-3' (nucleotides 1672-1698, Fig. 1 ). The cDNAs were phenol/chloroform extracted, precipitated in ethanol, resuspended in 10 mM Tris, 1 mM EDTA, and the 335-bp sequence in c-erbA" shown in Fig. 1 formed on one clone using the K/RT Universal Sequencing System (Promega Biotec), and the adenine sequence ofthe other cDNA clones was rapidly determined by single-lane sequence analysis (26). Amplification of the kindred A genomic sequence was done in the c-erbA# region shown in Fig. 1 . The 5' primer (GS1) was chosen to avoid an intron and had a PstI site constructed: 5'-AGGTGACAGAT-CTGCAGATGATAGGAG-3' (nucleotides 1556-1582, Fig. 1 ). Several genomic clones from affected members J.H. and B.H. were isolated and sequenced.
Protein modeling of the human placental and the kindred A cerbA# forms was done by Garnier structural analysis (PCGENE Software, Intelligenetics, Inc., Mountainview, CA).
Allelic-specific hybridization. The presence of a single nucleotide change, C to A, at position 1643 (coordinates according to reference 3) in genomic sequences ofkindreds A, B, and D, and ofrandom subjects was done using an 1 8mer, Pro, as probe for the wild-type sequence and another 18mer, His, as probe for the C to A substitution ( Fig. 1) . Samples of 0.5-1.0 ,ug of genomic DNA from affected members of all three kindreds and from 46 random individuals (i.e., 92 random cerbA# alleles) were used in the polymerase chain reaction to amplify the genomic sequence shown in Fig. 1 . All amplifications were verified by visualization ofthe 143-bp band on ethidium bromide-stained gels.
The amplified gemonic DNA samples were separated on 2% NuSieve/ 1% agarose minigels and transferred under alkaline conditions to Nytran membranes (27) . These Southern blots were prehybridized at 37'C in 5X SSPE, SX Denhardt's, 0.5% SDS, for I h, and hybridized with 1 X 106 cpm/ml of end-labeled His or Pro oligomers. The blots were washed twice for 5 min each at room temperature in 2x SSPE, 0.5% SDS, and then for 10 min at 55°C in SX SSPE, 0.5% SDS. Most of the random allelic sequences were additionally checked for hybridization to the His oligomer using a slot-blot method that has been previously described for allelic specific hybridization (28) .
Results
Phenotype ofthyroid hormone resistance kindreds. The levels of thyroid hormones and TSH for kindreds A, B, and D are shown in Table I . These kindreds all demonstrated inappropriately normal or elevated TSH with high levels of thyroid hormones. In addition to pituitary resistance to thyroid hormones, these kindreds also displayed varying patterns oftarget organ resistance to the action of thyroid hormones. Linkage between GTHR and c-erbAf3. We have previously reported that the gene for the syndrome of GTHR in kindred A was tightly linked to c-erbA# (22) . RFLPs observed with
BamHI and EcoRV restriction endonucleases and a c-erbAB cDNA probe cosegregated with the GTHR trait. The relationship between c-erbA,3 and the thyroid hormone resistance syndromes of kindreds B and D was also tested using linkage analysis. Linkage studies with the c-erbAa locus could not be readily accomplished since no high-frequency RFLPs were found using a c-erbAa cDNA probe and screening 10 normal subjects with 35 different restriction endonucleases. However, c-erbA# was linked to GTHR in both kindred B and kindred D. Nine members of kindred B were fully informative with the BamHI RFLP alone (Fig. 2) . Eight members of kindred D were informative when haplotyped with the combination of (Fig. 3) . Table II shows that the maximum logarithm of the odds scores between the GTHR and c-erbA$ loci were 3.91, 1.15, and 0.71 at a recombination fraction of 0 for kindreds A, B, and D, respectively. The summed logarithm of the odds score between GTHR and the c-erbA(3 gene was 5.77, which means there is an -1/600,000 probability that this cosegregation of c-erbA(3 and GTHR occurred through chance. The summed logarithm of the odds score tests the hypothesis that GTHR is caused in general by defects in cerbAB. Other recent linkage data also support this hypothesis (30) . The linkage of c-erbAf3 and GTHR in these three kindreds strongly suggests that c-erbAiB is an important thyroid hormone receptor in vivo and that genetic defects of cerbA# are responsible for thyroid hormone resistance in various tissues. Furthermore, the phenotypic variation among these kindreds raises the possibility that there may be differing genetic abnormalities of c-erbAf3, qualitative or quantitative, resulting in GTHR.
Variant sequence ofc-erbAf in kindred A. The genetic abnormality of c-erbAiB in kindred A was investigated using a modification of the polymerase chain reaction (26, 31). We focused on the COOH terminus sequence because it is crucial for the T3-binding property ofthe c-erbA proteins (32, 33) and previous Scatchard analysis of T3 binding from salt-extracted fibroblast nuclear receptors showed a significant reduction in T3-binding affinity in an affected member (B.H.) compared with that in normal subjects (1 1 erbAB. Symbols represented are as described in Fig. 2 In order to establish the authenticity of the adenine at 1643, and to determine if it was associated with the abnormal c-erbAfl-allele in kindred A, the genomic sequence of c-erbAfl in kindred A was analyzed. The intron-exon structure of cerbAB is not known, but we suspected it was similar to that of c-erbAa for which there is information on the 3' end (18) . An 89-bp gemonic sequence containing the putative adenine substitution in one allele from two affected members ofkindred A (J.H., B.H.) was amplified by the polymerase chain reaction (Fig. 1) . Several independent gemonic clones were sequenced and two alleles could be distinguished. There were two populations of genomic clones in approximately 1: 1 proportion, one containing cytosine at position 1643 (Pro codon 448) and one containing the adenine substitution (His codon). Thymine was found at positions 1636 and 1651 in both alleles. We next demonstrated that the His allele is the mutant allele in kindred A by testing all 17 members of kindred A for adenine 1643 using allelic-specific hybridization. Fig. 4 demonstrates that the adenine-1643 substitution was found in only one of the two alleles in the genomic sequence of all seven affected members of kindred A, but was not present in 10 unaffected members. This analysis demonstrated that the adenine 1643 marks the mutant allele.
Finally, we examined whether the adenine-1643 substitution was associated with GTHR in kindreds B and D which have different phenotypes, and whether it could be considered a variant sequence. Allelic-selective hybridization (Fig. 5) showed that affected members from kindred B and kindred D did not contain this sequence. In addition, 92 random cerbAj3-alleles were similarly analyzed by amplification/allelicselective hybridization and none hybridized to the HIS probe (data not shown). These data show that the adenine-1643 substitution, which generates a His codon, is not a polymorphism.
Discussion
Attempts to demonstrate alterations of T3 nuclear receptors in patients with GTHR using binding studies have generated ambiguous results, although more recent experiments with saltextracted nuclear receptors indicated defects in T3-binding affinity or receptor number among some, but not all, kindreds 1 1) . However, recent advances in molecular genetics have provided powerful new tools to address this problem and have enabled us to identify more directly possible receptor abnormalities in patients with GTHR.
There are two putative thyroid hormone receptor genes, c-erbAfl at 3p22 3p24.1 (36) and c-erbAa at 17q 11.2 -* 17q21 (37). Only one (-gene is present when the human placental c-erbA(3 cDNA is mapped in human gemonic clones (Bradley, W. E. C., personal communication). Consequently, the finding on linkage analysis of a lod score of 5.77 between GTHR and c-erbA(3 in three kindreds and identification of a mutation in c-erbA(3 in kindred A show that abnormalities in c-erbA(3 cause abnormal thyroid hormone action in diverse human tissues. A c-erbA(3 abnormality is linked with impaired thyroid hormone action with regard to general metabolism, liver, and pituitary affects in the three kindreds. The importance of a (3-type receptor, c-erbA,32, in the pituitary has been postulated on the basis of distribution of thyroid hormone receptor mRNAs in rat (21) . The His-448 mutation, the likely genetic defect in kindred A, is in a region shared by (31 and (2 isoforms and could theoretically disrupt thyroid hormone regulation mediated by either. The dependency in liver on cerbA( for thyroid hormone action is in concordance with the relative abundance in liver ofc-erbA(3 mRNAs compared with c-erbAa mRNAs (17). C-erbA(3 function in bone, brain, and heart appears to be more complex. In kindreds B and D abnormal (-receptors appear to be responsible for blunting thyroid hormone stimulation of heart rate, but this was not a constant feature in kindred A. Kindreds A and D had remarkable cognitive deficits, and affected members of kindred A had short stature associated with c-erbA(3. Overall, c-erbA(3 defects seem to be able to modify thyroid hormone responsiveness and/or result in clinical pathology in brain, heart, and in linear growth. Different c-erbA( mutations might result in different "dominant negative" effects in tissues (22, 38) . The estrogen and glucocorticoid receptors, members of the steroid/thyroid hormone receptor superfamily, undergo ligand-induced dimerization, and the dimers bind cognate DNA sequences (39, 40 (41) . It has also been shown that c-erbA proteins that lack a functional T3-binding domain can inhibit thyroid hormone action. Rat c-erbAa2, which does not bind T3, can inhibit T3 responses generated by rat c-erbA(3l or c-erbAa 1 (19, 20) . In addition, v-erbA can behave as a dominant negative inhibitor when coexpressed with its progenitor, the c-erbAa gene (42) . It is plausible that a point mutation in the wild-type receptor that disrupts the T3-binding domain would have a dominant negative function through either dimerization or repressor models (41, 42) .
The regulatory mechanism could be further convoluted if 15, 34, 35) . Most importantly, genomic sequences of random alleles contained bases T-1651 and T-1636 (data not shown), indicating they are wild-type bases and that a Phe-446 amino acid is the predicted wild-type residue. The base substitution at position 1643 marks the mutant allele in kindred A since it segregates with all affected members of kindred A, who were also shown to carry a wild-type allele by allelic specific hybridization.
Our data do not definitely prove that this variant sequence, resulting in a Pro-448 to His-448 codon alteration, is the mutation in c-erbA(3 responsible for GTHR in kindred A. However, it is certainly a likely candidate since it shows absolute linkage with the abnormal phenotype and has not been observed in 92 random individuals. Moreover, other data on the functional domains on the thyroid hormone receptors show that the COOH terminus is crucial for high-affinity T3 binding (32, 33) , and binding studies indicate abnormal T3 affinity for the kindred A receptor (11). Munoz et al. (32) have shown that a recombinant c-erbAa I receptor with a point mutation and a nine amino acid deletion in the COOH terminus which includes the PRO codon we have identified, diminishes T3 affinity 22-fold compared with the nonmutated a-construct (32 
